News

Avelumab fails against chemotherapy

Country
Germany

Avelumab, a checkpoint antibody that is the mainstay of Merck KGaA’s immuno-oncology portfolio, has failed to show superior overall survival in patients with metastatic gastric cancer compared with chemotherapy. The data is from a Phase 3 trial called Javelin Gastric 300.

Scientists create a zip file for DNA

Country
Switzerland

Normally, DNA coding is too big to be placed inside a cell. However researchers at ETH Zürich have developed a way of compressing DNA for delivery into a cell after which it is decompressed into its original state. They say the technique could assist the development of new medicines.

Vaccine against Type 1 diabetes underway

Country
Finland

Scientists at the University of Tampere in Finland and the Karolinska Institutet in Sweden have tested a vaccine targeting a pathogenic strain of an enterovirus in mice and found that it protected against Type 1 diabetes. The findings were reported in the 20 November 2017 edition of Diabetologia.

No clear benefit from lirilumab, nivolumab combination

Country
France

An immuno-oncology combination that had initially produced an objective response in a Phase 1/2 trial of patients with head and neck cancer, failed to show benefit in an extended patient population, Innate Pharma SA announced on 22 November.

Galapagos reports progress for CF drug

Country
Belgium

A new small molecule drug intended to treat cystic fibrosis patients with the F508del gene mutation has been well tolerated in patients in a Phase 2 study, paving the way for its use as part of a triple therapy, Galapagos NV announced on 19 November.

Amsterdam to be new home for EMA

Country
Netherlands

Amsterdam is to be the new home for the European Medicines Agency following Britain’s decision to leave the European Union, and give up its right to host EU institutions at the end of March 2019. The decision was announced on 20 November by the EU General Affairs Council.

Roche has two Phase 3 successes

Country
Switzerland

Roche has reported positive Phase 3 results for two different antibody therapeutics putting it in a leadership position for treating both non-small cell lung cancer and haemophilia A. The cancer trial was significant because it showed the benefits of using a checkpoint inhibitor as part of a triple therapy.

New FDA guidance for cells, tissues

Country
United States

The US Food and Drug Administrations has issued four guidance documents explaining how it intends to regulate products derived from human cells and tissues. The guidance updates rules that first took effect in 2005 and includes new incentives for developers of potentially life-saving therapies.

Meeting Report: Building the European capital market

Country
Germany

What will it take to build an integrated capital market in Europe? This question engaged executives at a BioEurope conference in Berlin on 6 to 8 November. The answer was both short and sweet, and long and complex.

Ablynx provides nine-month update

Country
Belgium

Ablynx NV, the Belgian antibody specialist, has released financial results for the first nine months of 2017 which show an operating loss due to significant outlays for research and development, but a strong cash balance. This was later augmented by a successful IPO on US Nasdaq.